Qihan Fu

2.6k total citations
44 papers, 1.5k citations indexed

About

Qihan Fu is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Qihan Fu has authored 44 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 13 papers in Molecular Biology and 10 papers in Cancer Research. Recurrent topics in Qihan Fu's work include Pancreatic and Hepatic Oncology Research (10 papers), Cancer Immunotherapy and Biomarkers (10 papers) and CAR-T cell therapy research (7 papers). Qihan Fu is often cited by papers focused on Pancreatic and Hepatic Oncology Research (10 papers), Cancer Immunotherapy and Biomarkers (10 papers) and CAR-T cell therapy research (7 papers). Qihan Fu collaborates with scholars based in China, United Kingdom and Japan. Qihan Fu's co-authors include Xueli Bai, Tingbo Liang, Yu Lou, Qida Hu, Qi Zhang, Xu Sun, Tao Wei, Yi Zheng, Weijia Fang and Zhou Tong and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Biomaterials.

In The Last Decade

Qihan Fu

43 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qihan Fu China 21 664 629 518 371 257 44 1.5k
Antonella Argentiero Italy 23 794 1.2× 596 0.9× 427 0.8× 406 1.1× 326 1.3× 48 1.6k
Yinan Deng China 17 504 0.8× 625 1.0× 491 0.9× 535 1.4× 174 0.7× 34 1.6k
Hao‐Xiang Wu China 22 596 0.9× 520 0.8× 393 0.8× 251 0.7× 289 1.1× 38 1.3k
Erbao Chen China 16 520 0.8× 511 0.8× 429 0.8× 456 1.2× 315 1.2× 37 1.3k
Jie-Yi Shi China 20 725 1.1× 471 0.7× 306 0.6× 620 1.7× 257 1.0× 31 1.6k
Peng–Yuan Zhuang China 16 706 1.1× 700 1.1× 491 0.9× 596 1.6× 191 0.7× 28 1.8k
Rakesh R. Ramjiawan United States 6 688 1.0× 434 0.7× 282 0.5× 449 1.2× 222 0.9× 7 1.3k
Tong‐Chun Xue China 22 501 0.8× 466 0.7× 321 0.6× 170 0.5× 174 0.7× 41 1.3k
Yong Yi China 27 905 1.4× 607 1.0× 474 0.9× 663 1.8× 236 0.9× 68 2.0k
Yu Lou China 15 416 0.6× 525 0.8× 403 0.8× 285 0.8× 150 0.6× 28 1.1k

Countries citing papers authored by Qihan Fu

Since Specialization
Citations

This map shows the geographic impact of Qihan Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qihan Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qihan Fu more than expected).

Fields of papers citing papers by Qihan Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qihan Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qihan Fu. The network helps show where Qihan Fu may publish in the future.

Co-authorship network of co-authors of Qihan Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Qihan Fu. A scholar is included among the top collaborators of Qihan Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qihan Fu. Qihan Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fu, Qihan, Hongkan Wang, Xingyuan Xu, et al.. (2024). Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 42(16_suppl). 4019–4019. 27 indexed citations
2.
Zhang, Hangyu, Zhi Yang, Xudong Zhu, et al.. (2024). Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion.. Journal of Clinical Oncology. 42(16_suppl). 3514–3514. 13 indexed citations
3.
Fu, Qihan, Yi Zheng, Weijia Fang, et al.. (2023). RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. EClinicalMedicine. 63. 102175–102175. 46 indexed citations
4.
5.
Fu, Qihan, Yiwen Chen, Chengxiang Guo, et al.. (2023). Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. Annals of Surgical Oncology. 30(8). 5071–5080. 16 indexed citations
6.
Dai, Xiaomeng, Xuanwen Bao, Qihan Fu, et al.. (2022). Development and validation of a meta-learning-based multi-modal deep learning algorithm for detection of peritoneal metastasis. International Journal of Computer Assisted Radiology and Surgery. 17(10). 1845–1853. 8 indexed citations
7.
Wang, Yangyang, Qihan Fu, Jianing Wang, et al.. (2022). Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade. Annals of Surgical Oncology. 29(12). 7619–7630. 6 indexed citations
8.
Dai, Xiaomeng, Yixuan Guo, Yan Hu, et al.. (2021). Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics. 11(7). 3489–3501. 57 indexed citations
9.
Liu, Lulu, Ruyi Zhang, Jingwen Deng, et al.. (2021). Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma. Cancer Immunology Immunotherapy. 71(1). 121–136. 82 indexed citations
10.
Li, Bin, Yan Cong, Jiamin Zhu, et al.. (2020). Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review. Frontiers in Immunology. 11. 1037–1037. 65 indexed citations
11.
Ye, Mao, Qi Zhang, Yiwen Chen, et al.. (2020). Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. HPB. 22(6). 821–832. 47 indexed citations
12.
Tu, Xiaoxuan, Xiangying Zhang, Shuwen Han, et al.. (2020). Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy. Supportive Care in Cancer. 28(11). 5569–5579. 20 indexed citations
13.
Fu, Qihan, Qi Zhang, Yu Lou, et al.. (2018). Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer. Oncogene. 37(47). 6105–6118. 123 indexed citations
14.
Zhang, Qi, Yu Lou, Jingying Zhang, et al.. (2017). Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Molecular Cancer. 16(1). 119–119. 99 indexed citations
15.
Ye, Long‐Yun, Wei Chen, Xueli Bai, et al.. (2016). Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis. Cancer Research. 76(4). 818–830. 233 indexed citations
16.
17.
Chen, Yiwen, Xueli Bai, Qi Zhang, et al.. (2016). The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway. Cancer Letters. 380(1). 98–105. 37 indexed citations
18.
Fu, Qihan, Qi Zhang, Jingying Zhang, et al.. (2015). LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation. Tumor Biology. 37(6). 7277–7286. 13 indexed citations
19.
Bai, Xueli, Qi Zhang, Long‐Yun Ye, et al.. (2014). Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas. Molecular Cancer Therapeutics. 13(8). 2062–2072. 31 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonella Argentiero Breakdown of academic impact, for papers by Yinan Deng Breakdown of academic impact, for papers by Hao‐Xiang Wu Breakdown of academic impact, for papers by Erbao Chen Breakdown of academic impact, for papers by Jie-Yi Shi Breakdown of academic impact, for papers by Peng–Yuan Zhuang Breakdown of academic impact, for papers by Rakesh R. Ramjiawan Breakdown of academic impact, for papers by Tong‐Chun Xue Breakdown of academic impact, for papers by Yong Yi Breakdown of academic impact, for papers by Yu Lou
Rankless by CCL
2026